Design, synthesis, and biological evaluation of novel p-tert -Butylcalix[4]arene derivatives bearing maleimide units as potential anticancer agents
Аннотация
In this study, a novel series of seven p -tert-butylcalix[4]arene derivatives functionalized with lower-rim aminomaleimide moieties (4a–g) was designed, synthesized, and evaluated for its in vitro antiproliferative potential. Initial biological screening against the U87-MG glioblastoma and normal L929 fibroblast cell lines identified the ethyl-substituted derivative (4b) and the benzyl-substituted derivative (4c) as early-stage screening hits with moderate activity, exhibiting IC 50 values of 55.94 ± 4.87 µM and 59.47 ± 7.60 µM, respectively. Compound 4b was selected for further evaluation due to its relatively more favorable selectivity profile (Selectivity Index = 3.72) against normal fibroblasts compared to 4c. Leveraging the intrinsic photophysical properties of the synthesized scaffold, the cellular internalization of 4b in U87-MG cells was visualized via confocal microscopy without the need for external fluorescent tagging. Subsequent in vitro evaluations provided preliminary flow cytometric evidence of dose-dependent apoptosis-associated cell death, showed an inhibition of clonogenic survival (reducing colony formation to 1.1%), and demonstrated the suppression of 3D tumor spheroid formation and growth. Consequently, the calix [4]arene-aminomaleimide framework is established not as a direct systemic anti-glioblastoma agent, but as a preliminary supramolecular screening hit. Its future development strictly requires significant structural optimization to improve its general physicochemical profile and efficacy, alongside the implementation of advanced localized delivery systems to overcome blood-brain barrier restrictions.